Unique Antibody Applications and other Solutions
Goodwin Delivers Solutions
Goodwin Biotechnology has many highly skilled scientists who thrive on challenges that, when solved, may develop into a biopharmaceutical candidate that addresses a significantly unmet clinical need.
To help combat the novel coronavirus (SARS-CoV-2) pandemic, Goodwin Biotechnology is prioritizing and staffing any biologics manufacturing project aimed at addressing this global healthcare crisis.
Exosomes are a novel form of biotherapeutics, but their production and purification are similar to conventional biologics manufacturing in terms of cell culture and bioreactor (upstream) and purification (downstream) development.
Biosimilars & Biobetters
Biologicals are a fast growing segment of the pharmaceutical market and over 30 branded biologics with sales in excess of $50 billion are facing patent expirations. That represents a significant business opportunity to develop a Biosimilar or even a Biobetter.
Multispecific Antibodies and Antibody Fragments
There is an increasing focus in the biopharmaceutical industry on the development of the next generation of complex biologics that allow the targeted delivery of products with multiple functionalities, increasing both efficacy and safety. Bi and multispecific antibodies and recombinant proteins are prime examples of new drug substances with the potential to offer higher potency with new mechanisms of action and increased safety profile.